Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profileAuthors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.
Al-Bawardy B, Quraishi M. Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251328606. PMID: 40144790, PMCID: PMC11938434, DOI: 10.1177/17562848251328606.Peer-Reviewed Original ResearchInflammatory bowel disease associated with primary sclerosing cholangitisPrimary sclerosing cholangitisOral vancomycinSclerosing cholangitisPooled analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply